Prophylaxis Against Hepatitis B Recurrence Posttransplantation Using Lamivudine and Individualized Low‐Dose Hepatitis B Immunoglobulin

Although the combination of lamivudine (LAM) and high‐dose intravenous (IV) hepatitis B immunoglobulin (HBIG) is very effective in preventing hepatitis B virus (HBV) recurrence after liver transplantation (LT), the major limitation of this regimen is its high cost. A more cost‐effective, convenient and widely accepted regimen is urgently needed. We evaluated the safety and efficacy of another strategy using LAM and individualized low‐dose intramuscular (IM) HBIG. Between May 2002 and December 2009, a total of 254 adult patients undergoing LT for HBV‐related benign end‐stage liver diseases received this regimen in our center. The mean follow‐up of these patients was 41.2 ± 22.7 months. Their 1‐, 3‐ and 5‐year survival rates were 85.3%, 77.4% and 76.4%, respectively, and 1‐, 3‐ and 5‐year HBV recurrence rates were 2.3%, 6.2% and 8.2%. Fourteen patients experienced posttransplant HBV recurrence. Pretransplant high viral load and posttransplant prednisone withdrawal time were observed to be associated with recurrence. In conclusion, combination therapy with LAM and individualized low‐dose IM HBIG provides a safe and effective prophylaxis against HBV recurrence after LT at about 5% of the cost of conventional high‐dose IV HBIG regimens.

[1]  J. Jang,et al.  Role of long‐term lamivudine treatment of hepatitis B virus recurrence after liver transplantation , 2008, Journal of medical virology.

[2]  G. Klintmalm,et al.  Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens , 2007, Clinical transplantation.

[3]  P. Angus,et al.  Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. , 2007, Gastroenterology.

[4]  M. Makuuchi,et al.  Liver Transplantation Using Hepatitis B Core Antibody−Positive Grafts: Review and University of Tokyo Experience , 2007, Digestive Diseases and Sciences.

[5]  C. Wai,et al.  Prophylactic strategies for hepatitis B patients undergoing liver transplant: A cost‐effectiveness analysis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  S. Karademir,et al.  Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. , 2006, Transplantation proceedings.

[7]  T. Liang,et al.  Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[8]  V. Mazzaferro,et al.  Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[9]  M. Rizzetto,et al.  Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  S. Cotler,et al.  Management of hepatitis B in liver transplant patients. , 2005, Journal of clinical gastroenterology.

[11]  D. Samuel,et al.  Evolving strategies to prevent HBV recurrence , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  J. Joh,et al.  Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. , 2004, Transplantation proceedings.

[13]  D. Samuel,et al.  HBV DNA persistence 10 years after liver transplantation despite successful anti‐HBS passive immunoprophylaxis , 2003, Hepatology.

[14]  S. Fan,et al.  Prophylaxis and treatment of recurrent hepatitis B after liver transplantation , 2003, Transplantation.

[15]  F. Chan,et al.  Immunosuppression with rapid steriod reduction among predominantly HBV liver transplantation recipients: initial experience. , 2003, Transplantation proceedings.

[16]  T. Berg,et al.  Increasing applicability of liver transplantation for patients with hepatitis B–related liver disease , 2002, Hepatology.

[17]  T. Berg,et al.  Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. , 2001, Transplantation.

[18]  N. Terrault,et al.  Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: A comparative study using a matched, untreated cohort , 2001, Hepatology.

[19]  F. Negro,et al.  Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. , 2001, Journal of hepatology.

[20]  M. Manns,et al.  Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. , 2001, Journal of hepatology.

[21]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[22]  E. Schiff,et al.  A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B , 2001, Hepatology.

[23]  T. Berg,et al.  Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation , 2000, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  P. Angus,et al.  Combination low‐dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[26]  J. Markmann,et al.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin , 1998, Hepatology.

[27]  T. Berg,et al.  Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high‐dose hepatitis B immune globulin after liver transplantation , 1998, Hepatology.

[28]  A. Lok,et al.  Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis , 1998, Hepatology.

[29]  A. Burroughs,et al.  Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis , 1996, The Lancet.

[30]  P. Angus,et al.  Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro , 1995, Hepatology.

[31]  G. Alexander,et al.  Liver transplantation in European patients with the hepatitis B surface antigen. , 1993, The New England journal of medicine.

[32]  D. V. van Thiel,et al.  Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease , 1991, Hepatology.

[33]  L. Poellinger,et al.  The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. , 1988, Virology.